Exicure, Inc. (NASDAQ:XCUR) Sees Large Growth in Short Interest

Exicure, Inc. (NASDAQ:XCUR) was the target of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 31,100 shares, an increase of 72.8% from the October 15th total of 18,000 shares. Based on an average trading volume of 1,030,000 shares, the short-interest ratio is currently 0.0 days. Currently, 4.7% of the shares of the company are short sold.

Exicure Trading Up 16.5 %

Shares of XCUR opened at $3.18 on Friday. Exicure has a 52 week low of $1.44 and a 52 week high of $6.00. The firm’s 50-day simple moving average is $2.71 and its 200 day simple moving average is $1.27.

Exicure (NASDAQ:XCUR) last posted its earnings results on Tuesday, August 13th. The company reported ($0.07) EPS for the quarter.

Insider Activity at Exicure

In related news, major shareholder Co. Ltd. Dgp acquired 237,223 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were bought at an average cost of $3.00 per share, with a total value of $711,669.00. Following the completion of the transaction, the insider now directly owns 849,223 shares of the company’s stock, valued at $2,547,669. This trade represents a 38.76 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 3.90% of the stock is owned by company insiders.

About Exicure

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.